SCHEDULE 13G/A: BlackRock Discloses 15.6% Passive Stake in Vanda Pharmaceuticals
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 15.6% beneficial ownership stake in Vanda Pharmaceuticals Inc. as of December 31, 2024.
Summary
- BlackRock, Inc. reported beneficial ownership of 9,104,204 shares of Vanda Pharmaceuticals Inc. common stock.
- This ownership represents 15.6% of Vanda Pharmaceuticals' outstanding common stock.
- BlackRock holds sole voting power over 8,179,929 shares and sole dispositive power over 9,104,204 shares.
- The filing is an Amendment No. 6 to a Schedule 13G, indicating a passive investment position.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a factual disclosure of beneficial ownership, not a performance report or strategic update, thus it carries a neutral sentiment.
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing is a standard disclosure required when an institutional investor's beneficial ownership in a public company exceeds a certain threshold (5% for Schedule 13G). It indicates BlackRock's significant, passive investment in Vanda Pharmaceuticals, a common practice for large asset managers.
Stakeholder Impact
- The disclosure of BlackRock's significant 15.6% stake may be viewed positively by shareholders as it indicates a major institutional investor's confidence in Vanda Pharmaceuticals.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (beneficial ownership threshold met) |
| 02/05/2025 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
BlackRock, Vanda Pharmaceuticals, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.